Download Files:
Products Details
Product Description
– Autotaxin-IN-4 (compound 51), extracted from patent WO2018212534A1, is an Autotaxin inhibitor. Autotaxin-IN-4 has the potential to treat idiopathic pulmonary fibrosis[1].
Web ID
– HY-135088
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C22H21N9O2
References
– [1]LEE, Dae Yon, et al. NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME. WO2018212534A1.
CAS Number
– 2156655-86-4
Molecular Weight
– 443.46
SMILES
– O=C(N1CCC(N=NN2)=C2C1)CC3=NC(C4=CN=C(NC5CC6=C(C=CC=C6)C5)N=C4)=NO3
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– Phosphodiesterase (PDE)
Isoform
– Autotaxin
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
